as 11-21-2024 3:30pm EST
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Founded: | 2007 | Country: | United States |
Employees: | N/A | City: | CAMBRIDGE |
Market Cap: | 336.2M | IPO Year: | 2014 |
Target Price: | $5.75 | AVG Volume (30 days): | 2.4M |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.23 | EPS Growth: | N/A |
52 Week Low/High: | $0.80 - $2.48 | Next Earning Date: | 11-07-2024 |
Revenue: | $169,879,000 | Revenue Growth: | -12.53% |
Revenue Growth (this year): | -11.57% | Revenue Growth (next year): | 6.13% |
AKBA Breaking Stock News: Dive into AKBA Ticker-Specific Updates for Smart Investing
PR Newswire
7 days ago
PR Newswire
9 days ago
Simply Wall St.
12 days ago
GuruFocus.com
14 days ago
Zacks
14 days ago
Associated Press Finance
14 days ago
PR Newswire
14 days ago
PR Newswire
20 days ago
The information presented on this page, "AKBA Akebia Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.